VanEck Pharmaceutical ETF (PPH)

ETF ยท Nasdaq

VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund listed on Nasdaq, where it has traded since December 20, 2011.

Type
Exchange-traded fund
Listed On
Nasdaq
Listed Since
December 20, 2011

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 148 institutions reported holding PPH, with 6.1 million shares worth $669.1 million in aggregate. The largest reported holder was Goldman Sachs, with 1.2 million shares worth $128.9 million. Of the 5 largest holders listed below, 3 added shares and 2 reduced their positions during the quarter.

InstitutionSharesValueQuarter change
Goldman Sachs1,178,974$129MAdded 19.56%
Morgan Stanley1,028,317$112MAdded 478.2%
UBS Group517,756$57MAdded 841.99%
Healthcare of Ontario Pension Plan Trust Fund402,000$44MReduced 28.34%
Bnp Paribas Financial Markets350,600$38MReduced 36.14%

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions

What is PPH?

VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund listed on Nasdaq, where it has traded since December 20, 2011.

Who are the largest institutional holders of PPH?

In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PPH were Goldman Sachs, Morgan Stanley and UBS Group.

How many institutions own PPH?

148 institutions reported a position in PPH for the quarter ended June 30, 2026, worth $669.1 million in total.

Did institutions buy or sell PPH last quarter?

Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter. Every reported holder and its change is on the SentiSense ownership page for PPH.

Every reported institutional holder, plus insider and congressional trades in PPH, on SentiSense.